1JF Apperlye.Mechanisms of resistance to imatinib in chronic myeloid leukacmia.Lancet Oncol,2007,8:1018.
2Landadio J,Deininger MW,Mauro MJ,et al.An intron-derived insertion/trun-cation mutation in the BCR-ABL kinase domain in chronic myeloid leukemia patients undergoing kinase inhibitor therapy.J Mol Dingn,2008,10:177.
3DL White,VA Saundets,P Dang,et al.Most CML patients who have a suboptimal response to imatinib have low OCT-l activity higher doses of imatinib may overcome the negative impact of low OCT-1 activity.Blood,2007,110:4064.
4HK Al Ali,M C Heinrich,T Lange,et al.High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.Hematol J,2004,5:55.
5S Soverini,S Colarossi,A Gnani,et al.Working Party on Chronic Myeloid Leukemia,contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients:by the GIMEMA Working Party on Chronic Myeloid Leukemia.Clin Cancer Bes,2006,12:7374.
6E.Weisberg,PW Manley,SW Cowan-Jacob,et al.Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myebid leukemia.Nat Rev.Cancer,2007.7:345.
7Ernst T,Erben P,M(u)ller MC,et al.Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib.Haematologica,2008,93:186.
8SG Willis,T Lange,S Demehri,et al.High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients:correlation with clonal cytogenetic evolution but not response to therapy.Blood,2005,106:2128.
9MB acearani,G Saglio,JM Goldman,et al.Evolving concepts in the management of chronic myeloid leukemia.Recommendations from an expert panel on behalf of the European Leukemia Net Blood,2006,108:1809.
10Wu J,Meng F,Lu H,et al.Lyn regulates BCR-ABL and Gab2 tyrosine phnsphorylatian and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells.Blood,2008,111(7):3821.
